Getting treatment within one week of a serious head injury can reduce the risk of developing Alzheimer’s disease by up to 41%, according to new…
Individuals with coronary artery disease (CAD)—a constricting or blocking of blood vessels feeding the heart—face increased risks of strokes, cognitive impairment and dementia. However, the…
Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer’s disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from…
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer’s disease, drugmaker Novo Nordisk announced on Nov.…
Researchers at Université Savoie Mont Blanc, Radboud University and the University of Oxford’s Wellcome Center for Integrative Neuroimaging, report that attenuation of the brain’s intrinsic…
Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms toxic tangles in…
Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape how scientists think about Alzheimer’s treatment.
A Korean research team has identified the most effective OLED color capable of enhancing cognitive function in Alzheimer’s patients. The OLED platform developed for this…
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and currently has no definitive cure. Although antibody-based therapies…
Combining genetic risk with cardiovascular disease risk factors—such as high LDL cholesterol, obesity, and hypertension—may predict who is more likely to develop dementia, according to…